Document Detail


Impact of transarterial therapy in hepatitis C-related hepatocellular carcinoma on long-term outcomes after liver transplantation.
MedLine Citation:
PMID:  21552101     Owner:  NLM     Status:  MEDLINE    
Abstract/OtherAbstract:
OBJECTIVES: To evaluate the impact of long-term outcomes of transarterial embolization (TAE) therapy in patients with hepatitis C virus (HCV)-related hepatocellular carcinoma (HCC) on the waiting list for liver transplantation (LT).
METHODS: We retrospectively evaluated the post-LT patients with HCV-related HCC who received TAE intervention (n=33) and those who had no treatment (n=47) while on the waiting list to determine long-term outcomes.
RESULTS: Over a 10-year period, of the 424 patients transplanted with HCV, 80 patients had HCC with a tumor burden within Milan criteria. For the entire study cohort, the mean duration of post-LT follow-up was 3.5 years; mean time of transplant waiting list was 120 days; and median post-LT survival was 8.9 years. The survival rates at 1, 3, 5, and 10 years were 82%, 70%, 55%, and 35%, respectively. From the study cohort, 33 patients received TAE and 47 patients did not while on the waiting list. The 2 groups were well matched, except, that the intervention patients received post-LT interferon more often and had a shorter time on the waiting list (56.2 d) when compared with the no treatment group (164.6 d, P<0.001). Median survival in the TAE group was 4.8 years and 8.9 years in the no treatment group. The recurrence rate was 15.6% in the treatment group and 6.9% in the no therapy group (P=0.275).
CONCLUSIONS: Pre-LT transarterial therapy has no benefit on post-LT survival and tumor recurrence in patients with HCV-related HCC who underwent a mean waiting period of <3 months to transplant.
Authors:
Roniel Cabrera; Renumathy Dhanasekaran; James Caridi; Virgina Clark; Giuseppe Morelli; Consuelo Soldevila-Pico; Joseph Magglioca; David Nelson; Roberto Jose Firpi
Publication Detail:
Type:  Journal Article; Research Support, N.I.H., Extramural    
Journal Detail:
Title:  American journal of clinical oncology     Volume:  35     ISSN:  1537-453X     ISO Abbreviation:  Am. J. Clin. Oncol.     Publication Date:  2012 Aug 
Date Detail:
Created Date:  2012-07-19     Completed Date:  2012-10-09     Revised Date:  2014-09-08    
Medline Journal Info:
Nlm Unique ID:  8207754     Medline TA:  Am J Clin Oncol     Country:  United States    
Other Details:
Languages:  eng     Pagination:  345-50     Citation Subset:  IM    
Export Citation:
APA/MLA Format     Download EndNote     Download BibTex
MeSH Terms
Descriptor/Qualifier:
Adult
Aged
Carcinoma, Hepatocellular / etiology,  mortality,  therapy*
Embolization, Therapeutic*
Female
Hepacivirus / pathogenicity
Hepatitis C / complications,  mortality,  virology*
Humans
Liver Neoplasms / etiology,  mortality,  therapy*
Liver Transplantation*
Male
Middle Aged
Neoplasm Recurrence, Local / diagnosis,  mortality,  therapy*
Neoplasm Staging
Prognosis
Retrospective Studies
Survival Rate
Waiting Lists
Grant Support
ID/Acronym/Agency:
K24 CA139570/CA/NCI NIH HHS; KL2 RR029888/RR/NCRR NIH HHS; KL2 RR029888-02/RR/NCRR NIH HHS; KL2 RR029888-03/RR/NCRR NIH HHS; UL1 TR000064/TR/NCATS NIH HHS
Comments/Corrections

From MEDLINE®/PubMed®, a database of the U.S. National Library of Medicine


Previous Document:  Where do Antiangiogenic Agents Belong in the Treatment Algorithm for Ovarian Cancer?
Next Document:  Flow Cytometric Evaluation of Skin Biopsies for Mycosis Fungoides.